SEP 12, 2018 12:00 PM PDT

ONETest PathoGenome: A Target Hybridization-Based Next-Generation Sequencing Assay to Tackle Undiagnosed Infections

Speaker

Abstract

Every year, approximately 800,000 critically ill patients are hospitals in the USA with undiagnosed infections. The only option is to treat these patients with broad-spectrum antimicrobial therapy and hope for the best outcome. The inability to obtain specific actionable information in a clinically relevant time-frame, combined with ineffective treatment, contributes to increased disease burden, mortality, hospitalizations, and drug resistance. The consequence is direct hospitalization costs of more than $27 billion, with another $26 billion lost due to antimicrobial resistance. What is urgently needed is precise and comprehensive targeted pathogen identification, including the capacity to detect drug-resistant mutations, for routine diagnosis to support effective treatment and control measures.
Fusion Genomics Corp.’s mission is to address this need and enable precision medicine for infectious diseases by developing a pan-pathogen test - the ONETest™ PathoGenome - that identifies all human pathogens (~1,400) and provides the genomic information necessary to guide treatment, including drug resistance and human genetic susceptibility markers in a timely fashion. The assay uses next-generation DNA sequencing (NGS) along with Fusion’s novel DNA hybridization technology, QuantumProbes, to enrich bacterial/viral/fungal genomes prior to sequencing. The assay will be functionally equivalent, yet clinically superior, to whole metagenome sequencing, but at 1/10th the cost, 1/3rd the time, and several times the sensitivity.

Learning Objectives: 

1. learn how NGS will impact undiagnosed infections  
2. learn about the advantages of using targeted sequencing versus whole metagenome sequencing


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
NOV 17, 2021 8:00 AM PST
C.E. CREDITS
NOV 17, 2021 8:00 AM PST
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
JUL 15, 2021 9:00 AM PDT
JUL 15, 2021 9:00 AM PDT
Date: July 15, 2021 Time: 9:00am (PDT), 12:00pm (EDT) The Pisces workflow robust, easy-to-use, end-to-end multi-omics solution for highly multiplexed targeted Spatial RNA analysis. VeranomeB...
SEP 12, 2018 12:00 PM PDT

ONETest PathoGenome: A Target Hybridization-Based Next-Generation Sequencing Assay to Tackle Undiagnosed Infections


Specialty

Laboratory Testing

Research

Research And Development

Health

Microbiology

Infectious Disease

T-Cells

Animal Behavior

Chemistry

Genomics

Animal Research

Cell Biology

Gene Sequencing

Systems Biology

Human Genetics

Geography

Asia75%

North America25%

Registration Source

Website Visitors100%

Job Title

Student25%

Educator/Faculty25%

QC/QA25%

Medical Laboratory Technician25%

Organization

Academic Institution50%

Manufacturer - Other25%

Other25%


Show Resources
Loading Comments...
Show Resources